Detection of Clone-Specific Immunoglobulin Heavy Chain Genes in the Bone Marrow of B-cell-Lineage Lymphoma after Treatment

Hoshino, Atsushi; Funato, Tadao; Munakata, Yasuhiko; Ishii, Tomonori; Abe, Shunsuke; Ishizawa, Kenichi; Ichinohasama, Ryo; Kameoka, Junichi; Meguro, Kuniaki; Sasaki, Takeshi

doi:10.1620/tjem.203.155

Cited by 4 publications

(3 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Since genetic analysis has become significant and is emphasized in the WHO classification, more detailed examinations such as polymerase chain reaction or DNA microarray analysis are applied for the evaluation of minimal residual disease and patients' prognoses, or for choosing therapeutic modalities (Morgensztern and Lossos 2005). Extranodal invasion of malignant cells may be common in patients with non Hodgkin's lymphoma (Hoshino et al 2004). Detection at the molecular level of minimal residual disease in extranodal organs may be useful as a predictor of prognosis for non Hodgkin's lymphoma (Hoshino et al 2004).…”

mentioning

confidence: 99%

See 1 more Smart Citation

Diffuse Large B-cell Lymphoma Arising in a Patient with Neurofibromatosis Type I and in a Patient with Neurofibromatosis Type II

Dohi

Hatori

Ichinohasama

et al. 2006

Tohoku J. Exp. Med.

Self Cite

View full text Add to dashboard Cite

We experienced two unusual cases of diffuse large B-cell lymphoma (DLBCL), which occurred in a patient with neurofibromatosis type I and a patient with neurofibromatosis type II. B-cell lymphoma is one of the most common phenotypic subgroups of malignant lymphoma. Neurofibromatosis I is characterized by café-au-lait spots and neurofibromas. Neurofibromatosis II typically consists of bilateral schwannomas of the acoustic nerve. Malignant lymphomas rarely coexist with neurofibromatosis I, and no coexistence with neurofibromatosis II has been reported. The patient with neurofibromatosis I was a 50-year-old Japanese woman, clinically manifesting von Recklinghausen's disease since infancy, who noticed an egg-sized tumor in her shoulder. The patient with neurofibromatosis II was a 39-year-old Japanese man who noticed multiple soft tissue tumors in his neck, buttock, and elbow. Biopsied materials from both cases were examined by multiparameter methods, including flow cytometry. Flow cytometry revealed large-scale cells to be tumor cells, and they were positive for CD19, CD20, and CD22. Both patients received chemotherapy, and the tumors disappeared. The patient with neurofibromatosis I was alive without recurrence at 4 years after treatment, while the patient with neurofibromatosis II died of recurrence. To the best of our knowledge, this is the first case of malignant lymphoma arising in a neurofibromatosis II patient. As for neurofibromatosis I, there were some reports about occurrence of malignant lymphoma. It is important to be aware of possibility of association of malignant tumors not only of the nervous system but also of unrelated to the nervous system when tumors appear in neurofibromatosis patients. malignant lymphoma; neurofibromatosis; flow cytometry; immunohistochemistry

show abstract

mentioning

confidence: 99%

“…Extranodal invasion of malignant cells may be common in patients with non Hodgkin's lymphoma (Hoshino et al 2004). Detection at the molecular level of minimal residual disease in extranodal organs may be useful as a predictor of prognosis for non Hodgkin's lymphoma (Hoshino et al 2004).…”

mentioning

confidence: 99%

Diffuse Large B-cell Lymphoma Arising in a Patient with Neurofibromatosis Type I and in a Patient with Neurofibromatosis Type II

Dohi

Hatori

Ichinohasama

et al. 2006

Tohoku J. Exp. Med.

Self Cite

View full text Add to dashboard Cite

show abstract

“…Several studies have shown that quantitative detection of minimal residual disease (MRD) 4 in lymphoid malignancies predicts the clinical outcome (1)(2)(3)(4)(5)(6)(7)(8)(9)(10)(11)(12). Monitoring treatment response by quantification of the tumor load is crucial to assess the risk of relapse and to identify those patients who may benefit from therapy reduction or intensification, reduction of immunosuppression for graft-vs-leukemia effect after stem cell transplantation, or adoptive T-cell therapy (13 ).…”

mentioning

confidence: 99%

Minimal Disease Detection and Confirmation in Hematologic Malignancies: Combining Cell Sorting with Clonality Profiling

Zehentner¹,

Fritschle²,

Stelzer³

et al. 2006

Clinical Chemistry

View full text Add to dashboard Cite

Background:In this study we demonstrate the technical application of flow cytometry and cell sorting combined with gene-rearrangement clonality profiling to detect and confirm minimal disease in 2 leukemia and 2 lymphoma cases. Methods: Specimens with low percentages (0.05%-5%) of abnormal lymphoid populations were identified by flow cytometry. The abnormal lymphoid populations were sorted by flow cytometry, and the purified tumor populations along with unsorted fractions were subsequently analyzed for the presence of clonal gene rearrangements by PCR and fluorescence-based capillary electrophoresis fragment analysis. Results: In 3 cases, distinct clonality profiles could be detected in the purified tumor cell fraction, and suspicious amplicons of identical sizes were detected among the polyclonal backgrounds in the unsorted specimens. For 1 patient, a monoclonal signal was detected in the sorted tumor cell fraction but not in the unseparated bone marrow specimen containing 0.05% abnormal lymphoblasts. A subsequent bone marrow specimen containing 4.8% recurring leukemia cells tested positive with a clonality profile that matched the previous profile in the sorted cell population. Conclusions: The described method integrating 2 technologies allows genotypic confirmation of an aberrant population detected by immunophenotype to increase

show abstract

Molecular Diagnostics for Minimal Residual Disease Analysis in Hematopoietic Malignancies

Zehentner¹

2018

Minimal Residual Disease Testing

View full text Add to dashboard Cite

Detection of Clone-Specific Immunoglobulin Heavy Chain Genes in the Bone Marrow of B-cell-Lineage Lymphoma after Treatment

Cited by 4 publications

References 32 publications

Diffuse Large B-cell Lymphoma Arising in a Patient with Neurofibromatosis Type I and in a Patient with Neurofibromatosis Type II

Diffuse Large B-cell Lymphoma Arising in a Patient with Neurofibromatosis Type I and in a Patient with Neurofibromatosis Type II

Minimal Disease Detection and Confirmation in Hematologic Malignancies: Combining Cell Sorting with Clonality Profiling

Molecular Diagnostics for Minimal Residual Disease Analysis in Hematopoietic Malignancies

Contact Info

Product

Resources

About